|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
JP7015244B2
(ja)
|
2016-03-22 |
2022-02-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化t細胞二重特異性分子
|
|
WO2017162587A1
(en)
*
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
US10111966B2
(en)
|
2016-06-17 |
2018-10-30 |
Magenta Therapeutics, Inc. |
Methods for the depletion of CD117+ cells
|
|
AU2017364818C1
(en)
|
2016-11-28 |
2025-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
|
CA3041279A1
(en)
|
2016-11-28 |
2018-05-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding domain, and polypeptide including conveying section
|
|
MD3558391T2
(ro)
|
2016-12-23 |
2022-05-31 |
Immunogen Inc |
Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora
|
|
BR112019012950A2
(pt)
|
2016-12-23 |
2019-11-26 |
Macrogenics, Inc. |
molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
|
|
SG11201906319XA
(en)
|
2017-01-20 |
2019-08-27 |
Magenta Therapeutics Inc |
Compositions and methods for the depletion of cd137+ cells
|
|
CA3053275A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Dragonfly Therapeutics, Inc. |
Proteins binding psma, nkg2d and cd16
|
|
SG11201909064RA
(en)
*
|
2017-03-30 |
2019-10-30 |
Merck Patent Gmbh |
Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
|
|
WO2018213335A1
(en)
*
|
2017-05-16 |
2018-11-22 |
Scalmibio, Inc. |
Activatable antibodies and methods of use thereof
|
|
WO2019023164A1
(en)
*
|
2017-07-24 |
2019-01-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
COMPOSITIONS AND METHODS FOR INDUCING PROTEIN FUNCTION
|
|
JP7801095B2
(ja)
|
2017-08-01 |
2026-01-16 |
エイビー セラピューティクス インコーポレイテッド |
二重特異性抗体およびその使用
|
|
KR20200089312A
(ko)
*
|
2017-11-28 |
2020-07-24 |
추가이 세이야쿠 가부시키가이샤 |
리간드 결합 활성을 조정 가능한 리간드 결합 분자
|
|
KR20250134208A
(ko)
|
2017-11-28 |
2025-09-09 |
추가이 세이야쿠 가부시키가이샤 |
항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
|
|
EP3717019A4
(en)
|
2017-11-28 |
2021-09-22 |
Board of Regents of the University of Nebraska |
RADIOPHARMACEUTICALS AND METHOD OF USE THEREOF
|
|
KR20260039804A
(ko)
*
|
2017-12-21 |
2026-03-20 |
아뮤닉스 파마슈티컬스, 인크. |
유리 세그먼트 및 이것을 포함하는 결합 조성물
|
|
BR112020023136A2
(pt)
|
2018-05-14 |
2021-02-09 |
Nuvation Bio Inc. |
compostos de alvo de receptor de hormônio nuclear anticâncer
|
|
CN112513081A
(zh)
|
2018-06-14 |
2021-03-16 |
生物蛋白有限公司 |
多重特异性抗体构建体
|
|
MX2020014290A
(es)
|
2018-06-22 |
2021-08-05 |
Cugene Inc |
Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
|
|
MX2020013466A
(es)
|
2018-06-26 |
2021-04-19 |
Immunogen Inc |
Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
|
|
EP3823611A1
(en)
*
|
2018-07-18 |
2021-05-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
MY204234A
(en)
|
2018-08-27 |
2024-08-16 |
Regeneron Pharma |
Use of raman spectroscopy in downstream purification
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
MX2021005048A
(es)
|
2018-10-31 |
2021-09-08 |
Bioatla Inc |
Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
|
|
WO2020113036A2
(en)
*
|
2018-11-28 |
2020-06-04 |
Promega Corporation |
Reactive peptide labeling
|
|
CN113660956B
(zh)
|
2019-01-28 |
2024-10-29 |
Ab诊疗公司 |
双特异性抗体及其用途
|
|
TWI739358B
(zh)
*
|
2019-03-25 |
2021-09-11 |
免疫功坊股份有限公司 |
帶有金屬結合區的複合多肽及其分子構建體
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
EP3981428A4
(en)
|
2019-06-05 |
2023-07-12 |
Chugai Seiyaku Kabushiki Kaisha |
Protease substrate, and polypeptide including protease cleavage sequence
|
|
CN114026127B
(zh)
|
2019-06-11 |
2024-10-29 |
生物蛋白有限公司 |
条件活性抗epcam抗体、抗体片段、其免疫缀合物以及其用途
|
|
US12048926B2
(en)
*
|
2019-06-26 |
2024-07-30 |
Waters Technologies Corporation |
Coatings with immobilized affinity ligands and enzymes and use thereof in liquid chromatography assays
|
|
KR102793948B1
(ko)
|
2019-08-07 |
2025-04-11 |
맙플렉스 인터내셔널 컴퍼니 리미티드 |
항체-약물 접합체 및 이의 용도
|
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP4058466A1
(en)
|
2019-11-13 |
2022-09-21 |
Amunix Pharmaceuticals, Inc. |
Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
|
|
CA3163358A1
(en)
|
2019-12-03 |
2021-06-10 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
|
WO2021136223A1
(en)
|
2019-12-31 |
2021-07-08 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Fusion proteins of glp-1 and gdf15 and conjugates thereof
|
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
CN115943210A
(zh)
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
PH12022553407A1
(en)
*
|
2020-06-25 |
2024-04-22 |
Amunix Pharmaceuticals Inc |
Her-2 targeted bispecific compositions and methods for making and using the same
|
|
CN116583532A
(zh)
*
|
2020-06-25 |
2023-08-11 |
阿穆尼克斯制药公司 |
靶向her-2的双特异性组合物以及其制造和使用方法
|
|
AU2021326469C1
(en)
*
|
2020-08-11 |
2026-04-30 |
Janux Therapeutics, Inc. |
Cleavable linker compositions and methods
|
|
EP4768463A2
(en)
*
|
2020-08-13 |
2026-07-01 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antibody drug conjugate
|
|
CA3193453A1
(en)
|
2020-09-30 |
2022-04-07 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Polypeptide conjugates and methods of uses
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
EP4259193A4
(en)
|
2020-12-09 |
2025-01-15 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
|
|
WO2022178754A1
(en)
*
|
2021-02-25 |
2022-09-01 |
Shanghai Allygen Biologics Co., Ltd. |
Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof
|
|
JP2024512392A
(ja)
|
2021-03-08 |
2024-03-19 |
イミュノジェン・インコーポレーテッド |
がんの治療のためのadam9を標的とする免疫抱合体の有効性を増加させるための方法
|
|
EP4313991A1
(en)
|
2021-03-23 |
2024-02-07 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN113215195B
(zh)
*
|
2021-04-30 |
2023-04-11 |
四川大学 |
一种在肌源性细胞特异性高表达sia的重组表达载体及其应用
|
|
WO2022235585A1
(en)
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20240017024A
(ko)
*
|
2021-06-04 |
2024-02-06 |
이뮤노젠 아이엔씨 |
가용성 fr-알파를 이용한 환자의 암 치료
|
|
CN117500885A
(zh)
*
|
2021-06-10 |
2024-02-02 |
罗塞洛公司 |
具有低热原活性的可交联官能化的明胶
|
|
CN116143935A
(zh)
*
|
2021-11-22 |
2023-05-23 |
杭州翰思生物医药有限公司 |
重组抗体及其应用
|
|
CN114672450B
(zh)
*
|
2022-01-26 |
2022-11-11 |
中山大学附属第一医院 |
一种分离纯化卵泡膜细胞的方法
|
|
US12405254B2
(en)
*
|
2022-02-18 |
2025-09-02 |
Dionex Corporation |
Low temperature oligosaccharide analytical system and method
|
|
WO2023161853A1
(en)
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Activatable il-18 polypeptides
|
|
EP4323413A4
(en)
|
2022-03-30 |
2025-10-15 |
Beijing Ql Biopharmaceutical Co Ltd |
LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
|
|
CN114965426B
(zh)
*
|
2022-05-17 |
2025-07-11 |
南京师范大学 |
一种膜ⅰ型基质金属蛋白酶活性检测方法
|
|
WO2024020486A2
(en)
*
|
2022-07-20 |
2024-01-25 |
Fuse Biotherapeutics Inc. |
Receptor tyrosine kinase-like orphan receptor 1 (ror1)-specific vhh antibodies and multispecific antibodies thereof as immune cell engagers
|
|
CN118126116A
(zh)
*
|
2022-12-01 |
2024-06-04 |
核欣(苏州)医药科技有限公司 |
异二聚体及其放射性医药用途
|
|
CN116077686B
(zh)
*
|
2022-12-15 |
2025-06-27 |
苏州智核生物医药科技有限公司 |
可酶切Linker及其用途
|
|
CN116199747A
(zh)
*
|
2022-12-26 |
2023-06-02 |
中国医学科学院医药生物技术研究所 |
一种力达霉素前药、制备方法及其在制备抗肿瘤药物中的应用
|
|
WO2024150174A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
WO2025041101A1
(en)
|
2023-08-23 |
2025-02-27 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
CN122349537A
(zh)
|
2023-12-01 |
2026-07-07 |
阿布林克斯有限公司 |
识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体
|
|
CN119033950B
(zh)
*
|
2024-08-23 |
2025-11-11 |
武汉大学 |
氧氟沙星或其衍生物与pd-1单克隆抗体偶联物及其应用
|
|
WO2026083296A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
|
|
WO2026083295A1
(en)
|
2024-10-16 |
2026-04-23 |
Bright Peak Therapeutics Ag |
Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains
|
|
US20260109746A1
(en)
|
2024-10-22 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd4-targeted il-15 molecules and methods of use
|